Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 5, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

527

Introducing pro and con discussions in ESMO Open-Cancer Horizons

C Zielinski1, M Preusser2, A Berghoff2

  • 1Wiener Privatklinik and Central European Cancer Center, Vienna, Austria.

ESMO Open
|July 7, 2022
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Experiment Videos

Last Updated: Sep 5, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

527
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.7K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.

ESMO open·2026
Same author

Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Gastroesophageal Cancer-A Real-World Experience.

Clinical oncology (Royal College of Radiologists (Great Britain))·2026
Same author

Peripheral blood DNA methylation profile and immune checkpoint inhibitor response in cancer patients.

ESMO open·2026
Same author

Predictive potential of patient-specific immunological characteristics in solid cancers: circulating monocytes, myeloid-derived suppressor cells, T cells, and the T-cell receptor repertoire.

ESMO open·2026
Same author

ESMO-Magnitude of Clinical Benefit Scale version 2.0 (ESMO-MCBS v2.0).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Response to letter re: Ethnic origin in cancer clinical trials: overrated or understated? A comprehensive analysis of cancer clinical trials leading to FDA and EMA approvals between 2020 and 2022.

ESMO open·2025